Current biomarkers for AD target the dominant pathological paradigm, characterized by beta-amyloid and tau pathologies, as well as neurodegenerative changes. While much of the pathologic evidence of AD is found in gray matter, it is well recognized that concomitant white matter (WM) alterations ...